JAZZ (Jazz Pharmaceuticals) Long-Term Debt: $4,324 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JAZZ Jazz Pharmaceuticals PLC JAZZ
73 GF Score
Price $256.92
GF Value $150.47
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Long-Term Debt?

Jazz Pharmaceuticals JAZZ +0.58% 73 Long-Term Debt is $4,324 Mil as of Mar. 2026. GuruFocus rates JAZZ with a GF Score™ of 73/100 and a GF Value™ of $150.47 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Jazz Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2026 was $4,324 Mil.

Jazz Pharmaceuticals's quarterly Long-Term Debt declined from Sep. 2025 ($4,332 Mil) to Dec. 2025 ($4,328 Mil) and declined from Dec. 2025 ($4,328 Mil) to Mar. 2026 ($4,324 Mil).

Jazz Pharmaceuticals's annual Long-Term Debt increased from Dec. 2023 ($5,108 Mil) to Dec. 2024 ($6,078 Mil) but then declined from Dec. 2024 ($6,078 Mil) to Dec. 2025 ($4,328 Mil).

Jazz Pharmaceuticals  (NAS:JAZZ) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Jazz Pharmaceuticals Long-Term Debt Related Terms

Jazz Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Long-Term Debt Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,018.94 5,693.34 5,107.99 6,077.64 4,328.35

Jazz Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,336.48 4,335.62 4,331.98 4,328.35 4,324.20
JAZZ
73GF Score
Jazz Pharmaceuticals PLC JAZZ
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $4,324 Mil mean?
Jazz Pharmaceuticals (JAZZ) has a Long-Term Debt of $4,324 Mil as of Mar. 2026.
Is Jazz Pharmaceuticals' Long-Term Debt too high?
Jazz Pharmaceuticals' current Long-Term Debt is $4,324 Mil. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Long-Term Debt compare to BBIO and ASND?
Jazz Pharmaceuticals' Long-Term Debt of $4,324 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Jazz Pharmaceuticals's current Long-Term Debt is $4,324 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (JAZZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $150.47, compared to a current price of $256.92 — trading 70.7% above its estimated fair value. The current Long-Term Debt is $4,324 Mil. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Jazz Pharmaceuticals (JAZZ), the current Long-Term Debt is $4,324 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of $256.92 is trading 70.7% above its estimated GF Value™ of $150.47. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for JAZZ:

  • Long-Term Debt: $4,324 Mil
  • GF Value™: $150.47 vs. price of $256.92 (70.7% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for JAZZ

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$256.92
Price
$150.47
GF Value